Author(s): Fonseca-Gomes, João ; Loureiro, Joana A ; Tanqueiro, Sara ; Mouro, Francisco ; Ruivo, Pedro ; Carvalho, Tânia ; Sebastião, Ana M ; Diógenes, Maria José ; Pereira, Maria Carmo
Date: 2020
Persistent ID: http://hdl.handle.net/10451/47280
Origin: Repositório da Universidade de Lisboa
Subject(s): PLGA nanoparticles; Drug delivery systems; Liposomes; Long-lasting treatment; Nanocarriers; Solid lipid nanoparticles
Nanoparticles (NPs), as drug delivery systems, appear to be a promising tool for prolonged therapeutic strategies as they allow a controlled drug release over time. However, most of the studies found in the literature simply contemplate the use of a single or low number of dosages with low NPs concentrations. In the context of chronic diseases, like Alzheimer's disease, cancer or human immunodeficiency virus (HIV), where the therapeutic scheme is also chronic, studies with numerous repeated dosages are often neglected.
